A new trading day began on Friday, with Adaptive Biotechnologies Corp (NASDAQ: ADPT) stock price down -8.96% from the previous day of trading, before settling in for the closing price of $5.58. ADPT’s price has ranged from $2.28 to $6.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 27.46% over the last five years. Meanwhile, its annual earnings per share averaged 28.66%. With a float of $142.73 million, this company’s outstanding shares have now reached $145.08 million.
The firm has a total of 709 workers. Let’s measure their productivity. In terms of profitability, gross margin is 53.84%, operating margin of -93.9%, and the pretax margin is -110.17%.
Adaptive Biotechnologies Corp (ADPT) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Adaptive Biotechnologies Corp is 3.37%, while institutional ownership is 92.14%. The most recent insider transaction that took place on Aug 22 ’24, was worth 121,079. In this transaction SVP and General Counsel of this company sold 26,922 shares at a rate of $4.50, taking the stock ownership to the 139,365 shares. Before that another transaction happened on Aug 22 ’24, when Company’s Officer proposed sale 26,922 for $4.50, making the entire transaction worth $121,079.
Adaptive Biotechnologies Corp (ADPT) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 28.66% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.60% during the next five years compared to -32.91% drop over the previous five years of trading.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Trading Performance Indicators
Here are Adaptive Biotechnologies Corp’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.94 in one year’s time.
Technical Analysis of Adaptive Biotechnologies Corp (ADPT)
Analysing the last 5-days average volume posted by the [Adaptive Biotechnologies Corp, ADPT], we can find that recorded value of 1.3 million was lower than the volume posted last year of 1.41 million. As of the previous 9 days, the stock’s Stochastic %D was 28.45%. Additionally, its Average True Range was 0.43.
During the past 100 days, Adaptive Biotechnologies Corp’s (ADPT) raw stochastic average was set at 52.91%, which indicates a significant increase from 24.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 97.17% in the past 14 days, which was higher than the 76.50% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.95, while its 200-day Moving Average is $3.98. Now, the first resistance to watch is $5.56. This is followed by the second major resistance level at $6.03. The third major resistance level sits at $6.27. If the price goes on to break the first support level at $4.84, it is likely to go to the next support level at $4.59. Now, if the price goes above the second support level, the third support stands at $4.12.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Key Stats
With a market capitalization of 682.52 million, the company has a total of 147,579K Shares Outstanding. Currently, annual sales are 170,280 K while annual income is -225,250 K. The company’s previous quarter sales were 46,440 K while its latest quarter income was -32,070 K.
